Discovery and Characterization of Selective, First-in-Class Inhibitors of Citron Kinase
Journal of Medicinal Chemistry · 22.02.2024 · 67 (4) · 2631-2666
DOI: 10.1021/acs.jmedchem.3c01807 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 08.02.2024. Verfasst von Joshua J Maw und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Therapeutics Discovery, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Cytokinesis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Dr. Ralph and Marian Falk Medical Research Trust, Lerner Research Institute, Cleveland Clinic, Cleveland Clinic Foundation.
Abstract (Originalsprache)
Citron kinase (CITK) is an AGC-family serine/threonine kinase that regulates cytokinesis. Despite knockdown experiments implicating CITK as an anticancer target, no selective CITK inhibitors exist. We transformed a previously reported kinase inhibitor with weak off-target CITK activity into a first-in-class CITK chemical probe, C3TD879. C3TD879 is a Type I kinase inhibitor which potently inhibits CITK catalytic activity (biochemical IC50 = 12 nM), binds directly to full-length human CITK in cells (NanoBRET Kd 17-fold versus 373 other human kinases), making C3TD879 the first chemical probe suitable for interrogating the complex biology of CITK. Our small-molecule CITK inhibitors could not phenocopy the effects of CITK knockdown in cell proliferation, cell cycle progression, or cytokinesis assays, providing preliminary evidence that the structural roles of CITK may be more important than its kinase activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Therapeutics Discovery, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States.
- Broad Institute of MIT and Harvard, 415 Main Street, Cambridge Massachusetts 02142, United States.
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States.
ORCID-Profile: Jesse A Coker, Christopher M Goins, Dhiraj Sonawane, Jonathan D Macdonald, Shaun R Stauffer
Förderung
- Dr. Ralph and Marian Falk Medical Research Trust
- Lerner Research Institute, Cleveland Clinic
- Cleveland Clinic Foundation
Zitieren
APA
Maw, J. J., Coker, J. A., Arya, T., Goins, C. M., Sonawane, D., Han, S. H., Rees, M. G., Ronan, M. M., Roth, J. A., Wang, N. S., Heemers, H. V., Macdonald, J. D., & Stauffer, S. R. (2024). Discovery and Characterization of Selective, First-in-Class Inhibitors of Citron Kinase. Journal of Medicinal Chemistry, 67(4), 2631-2666. https://doi.org/10.1021/acs.jmedchem.3c01807
Vancouver
Maw JJ, Coker JA, Arya T, Goins CM, Sonawane D, Han SH, et al. Discovery and Characterization of Selective, First-in-Class Inhibitors of Citron Kinase. Journal of Medicinal Chemistry. 2024;67(4):2631-2666. doi:10.1021/acs.jmedchem.3c01807
BibTeX
@article{Maw2024,
author = {Maw, Joshua J and Coker, Jesse A and Arya, Tarun and Goins, Christopher M and Sonawane, Dhiraj and Han, Sang Hoon and Rees, Matthew G and Ronan, Melissa M and Roth, Jennifer A and Wang, Nancy S and Heemers, Hannelore V and Macdonald, Jonathan D and Stauffer, Shaun R},
title = {Discovery and Characterization of Selective, First-in-Class Inhibitors of Citron Kinase},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {4},
pages = {2631--2666},
doi = {10.1021/acs.jmedchem.3c01807}
}
EUVIMED